These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33433135)

  • 1. Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients.
    Wang JK; Huang TL; Hsu YR; Chang PY
    J Chin Med Assoc; 2021 Mar; 84(3):326-330. PubMed ID: 33433135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes of Taiwanese patients with treatment-naïve diabetic macular edema.
    Wang JK; Huang TL; Chang PY
    J Formos Med Assoc; 2020 Nov; 119(11):1619-1625. PubMed ID: 32482606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
    Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
    BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema.
    Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Monferrer-Adsuara C; Hernández-Bel L; Montero-Hernández J
    BMC Ophthalmol; 2019 Jan; 19(1):15. PubMed ID: 30634940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study.
    Iglicki M; Busch C; Zur D; Okada M; Mariussi M; Chhablani JK; Cebeci Z; Fraser-Bell S; Chaikitmongkol V; Couturier A; Giancipoli E; Lupidi M; Rodríguez-Valdés PJ; Rehak M; Fung AT; Goldstein M; Loewenstein A
    Retina; 2019 Jan; 39(1):44-51. PubMed ID: 29697589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.
    Zur D; Iglicki M; Busch C; Invernizzi A; Mariussi M; Loewenstein A;
    Ophthalmology; 2018 Feb; 125(2):267-275. PubMed ID: 28935399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema.
    Bolukbasi S; Cakir A; Erden B; Karaca G
    Cutan Ocul Toxicol; 2019 Dec; 38(4):401-405. PubMed ID: 31438736
    [No Abstract]   [Full Text] [Related]  

  • 13. Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients.
    Bux AV; Fortunato F; Barone A; Russo V; Delle Noci N; Iaculli C
    Eur J Ophthalmol; 2022 May; 32(3):1619-1626. PubMed ID: 34120496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
    Boyer DS; Yoon YH; Belfort R; Bandello F; Maturi RK; Augustin AJ; Li XY; Cui H; Hashad Y; Whitcup SM;
    Ophthalmology; 2014 Oct; 121(10):1904-14. PubMed ID: 24907062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes.
    Özdemir HB; Hasanreisoğlu M; Yüksel M; Ertop M; Gürelik G; Özdek Ş
    Turk J Ophthalmol; 2019 Dec; 49(6):323-327. PubMed ID: 31893587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
    Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
    Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema.
    Güler E; Totan Y; Betül Güragaç F
    Cutan Ocul Toxicol; 2017 Jun; 36(2):180-184. PubMed ID: 28366074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients.
    Dang Y; Mu Y; Li L; Mu Y; Liu S; Zhang C; Zhu Y; Xu Y
    Drug Des Devel Ther; 2014; 8():1441-9. PubMed ID: 25258512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.
    Mitchell P; Arnold J; Fraser-Bell S; Kang HK; Chang AA; Tainton J; Simonyi S
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37541745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.